CLEC12A (C-Type Lectin Domain Family 12 Member A) also as so as MICL, it is a Protein Coding gene. CLEC12A/MICL is a cell surface receptor known to regulate signaling cascades and facilitate the tyrosine phosphorylation of target MAP kinases. CLEC12A plays an important immunomodulatory role in AML, CLEC12A is an ideal chimeric antigen receptor T-cell (CAR-T) therapy target for AML and its expression level was closely linked to treatment response and patients' survival outcome. it was highly expressed in AML cell lines and in tissues from AML patients and a higher CLEC12A expression in leukemia stem cells. CLEC12A low expression was associated with poor prognosis in the chemotherapy-only group and high CLEC12A expression may benefit from autologous or allogeneic hematopoietic stem cell transplantation (HSCT). Diseases associated with CLEC12A include Myeloid Leukemia and 3Mc Syndrome.